Advertisement
AZN vs GSK
Which Stock Would AI Choose? AstraZeneca (AZN) vs. GSK (GSK) Stock Comparison
Key Takeaways
- AstraZeneca (AZN) delivered a third-quarter earnings beat driven by 17% oncology growth, while GSK (GSK) also beat estimates but saw its shares fall on weakening vaccine demand.
- Relative performance diverged sharply: AZN climbed toward a technical breakout above its 200-day moving average, whereas GSK posted its steepest single-day decline in months.
- AstraZeneca's restructuring targets roughly $1.5 billion in annual savings by 2029 and management sees over $20 billion in potential peak sales from 2027 trial readouts.
- GSK is executing a strategic overhaul under a new CEO but faces patent-expiry pressure on its blockbuster HIV medicine and softer Shingrix sales.
- Tickeron AI Verdict: The AI would currently favor AstraZeneca (AZN) as the ticker of choice, based on stronger trend consistency, earnings momentum, and clearer near-term catalysts.
- For more context on each name, explore AZN Major News and AZN Today's Price Move, as well as GSK Major News and GSK Today's Price Move.
- To see how automated strategies are positioning across the market, explore the curated Trending AI Robots.
Introduction
AstraZeneca (AZN) and GSK (GSK) are two of the world's largest pharmaceutical companies and frequent subjects of investor debate over which offers the more compelling blend of growth, pipeline depth, and valuation. This stock comparison examines their recent performance, growth drivers, and market positioning to help both long-term investors and active traders assess relative strength. Because the two firms operate in the same sector but are navigating different strategic phases, their divergence in momentum and sentiment offers a useful case study in how headline earnings results can translate into very different share-price reactions.
AZN Overview and Recent Performance
AstraZeneca is a global biopharmaceutical leader with a diversified portfolio spanning oncology, cardiovascular, respiratory, and rare-disease treatments. In recent weeks, the company reported third-quarter revenue of $16.21 billion, up 7% at constant exchange rates and ahead of consensus, while core earnings per share (EPS, a profitability measure that strips out one-time items) rose 17% to $2.79, beating estimates. Oncology was the standout, with sales up 17%, though diabetes drug Farxiga declined 25% amid generic competition.
The results were accompanied by a restructuring program targeting about $1.5 billion in annual savings by 2029, plus management's reiteration of its $80 billion revenue ambition for 2030. Sentiment improved as the stock moved to reclaim its 200-day moving average, a widely watched trend indicator. Analysts at Jefferies and UBS reiterated buy ratings following the update, reflecting a favorable near-term view of the company's execution and margin trajectory.
GSK Overview and Recent Performance
GSK is a British pharmaceutical and vaccine maker whose business spans specialty medicines, general medicines, and vaccines. In the same recent reporting period, GSK posted third-quarter revenue of £8.89 billion, up 5% at constant currency and slightly above expectations, with core EPS of 54.6 pence versus a 50.4 pence consensus. Specialty medicines grew 15%, led by HIV and respiratory products, reinforcing progress under CEO Luke Miels, who took charge at the start of 2026.
Despite the headline beat, shares fell as much as 5.4% in a single session, their largest drop in months, as investors focused on a 2% decline in vaccine sales, softer Shingrix demand, and a £328 million restructuring charge tied to its savings program. The company reaffirmed rather than raised full-year guidance, and it continues to work through patent-expiry risks on the blockbuster HIV medicine dolutegravir between 2028 and 2030. This mixed reaction illustrates how composition of growth can matter as much as the growth itself.
Trending AI Robots
For traders seeking a systematic view of market positioning, Tickeron's Trending AI Robots page offers a curated look at the platform's most relevant automated strategies. Tickeron maintains hundreds of AI trading bots across thousands of tickers, but only a select group earns a place in this featured section. The page highlights roughly two dozen top bots selected from a broader pool, each with its own trading style, timeframe, and performance metrics, including realized return, win rate, and profit factor. These robots vary widely in strategy, from short-interval momentum to counter-trend approaches, allowing users to compare statistics side by side. Browsing the list is a practical way to see how AI-driven strategies are currently allocating attention across sectors.
Head-to-Head Comparison
The most visible contrast between these two stocks lies in recent momentum. AstraZeneca's (AZN) earnings beat translated into renewed buying interest and a push above a key technical level, while GSK's (GSK) beat was met with selling as investors weighed soft vaccine results and an unchanged outlook. In terms of growth drivers, AstraZeneca is leaning heavily on its oncology franchise and a large late-stage pipeline, whereas GSK is rebuilding around specialty medicines and new launches while managing the gradual erosion of older products.
Risk profiles also differ. AstraZeneca faces generic pressure on Farxiga and near-term restructuring costs, but it benefits from a broader revenue base and clearer 2030 visibility. GSK carries concentrated patent-expiry exposure in HIV and greater sensitivity to vaccine demand cycles, even as its cost-savings program aims to fund research and development (R&D) investment. On sector exposure, both are defensive healthcare names, but AstraZeneca's faster-growing oncology mix has attracted stronger relative positioning in recent trading, while GSK's valuation and dividend profile appeal to more income-oriented investors.
Tickeron AI Verdict
Based on observable factors such as trend consistency, earnings momentum, and the clarity of near-term catalysts, Tickeron's AI would likely favor AstraZeneca (AZN) over GSK (GSK) in the current environment. AstraZeneca's combination of an earnings beat, expanding margins, a technical reclaim of its 200-day moving average, and a pipeline narrative tied to substantial 2027 readouts presents a more constructive setup. GSK's story remains credible but is currently complicated by declining vaccine sales and investor skepticism over restructuring execution. This assessment is probabilistic rather than definitive, reflecting the balance of recent data rather than a guarantee of future performance.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AZN is a Buy and GSK is a Buy.
Momentum Indicator for AZN turns positive, indicating new upward trend
AZN saw its Momentum Indicator move above the 0 level on October 14, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 79 similar instances where the indicator turned positive. In 51 of the 79 cases, the stock moved higher in the following days. The odds of a move higher are at 65%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for AZN just turned positive on October 15, 2026. Looking at past instances where AZN's MACD turned positive, the stock continued to rise in 24 of 42 cases over the following month. The odds of a continued upward trend are 57%.
AZN moved above its 50-day moving average on October 14, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for AZN crossed bullishly above the 50-day moving average on October 21, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 8 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 53%.
Following a +10.11% 3-day Advance, the price is estimated to grow further. Considering data from situations where AZN advanced for three days, in 190 of 335 cases, the price rose further within the following month. The odds of a continued upward trend are 57%.
The Aroon Indicator entered an Uptrend today. In 142 of 263 cases where AZN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 54%.
Bearish Trend Analysis
The 10-day RSI Indicator for AZN moved out of overbought territory on November 10, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 36 similar instances where the indicator moved out of overbought territory. In 16 of the 36 cases, the stock moved lower in the following days. This puts the odds of a move lower at 44%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 18 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AZN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 45%.
AZN broke above its upper Bollinger Band on October 30, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 13 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 59, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. AZN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 44 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 54 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.749) is normal, around the industry mean (-1.421). P/E Ratio (27.660) is within average values for comparable stocks, (21.700). Projected Growth (PEG Ratio) (1.168) is also within normal values, averaging (5.738). Dividend Yield (0.023) settles around the average of (0.038) among similar stocks. P/S Ratio (4.148) is also within normal values, averaging (4.033).
GSK's RSI Oscillator climbs out of oversold territory
The RSI Oscillator for GSK moved out of oversold territory on October 07, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 23 similar instances when the indicator left oversold territory. In 15 of the 23 cases the stock moved higher. This puts the odds of a move higher at 65%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on GSK as a result. In 48 of 77 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 62%.
The Moving Average Convergence Divergence (MACD) for GSK just turned positive on November 04, 2026. Looking at past instances where GSK's MACD turned positive, the stock continued to rise in 29 of 46 cases over the following month. The odds of a continued upward trend are 63%.
GSK moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for GSK crossed bullishly above the 50-day moving average on October 27, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 55%.
Following a +3.43% 3-day Advance, the price is estimated to grow further. Considering data from situations where GSK advanced for three days, in 202 of 320 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.
The Aroon Indicator entered an Uptrend today. In 145 of 258 cases where GSK Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 56%.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GSK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 55%.
GSK broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 34 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 37 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 59, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 46 (best 1 - 100 worst), indicating fairly steady price growth. GSK’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 81 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.715) is normal, around the industry mean (-1.421). P/E Ratio (20.988) is within average values for comparable stocks, (21.700). Projected Growth (PEG Ratio) (6.052) is also within normal values, averaging (5.738). Dividend Yield (0.035) settles around the average of (0.038) among similar stocks. P/S Ratio (2.294) is also within normal values, averaging (4.033).
AZN | GSK | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 75 | 73 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 65 Fair valued | 81 Overvalued | |
PROFIT vs RISK RATING 1..100 | 13 | 37 | |
SMR RATING 1..100 | 44 | 34 | |
PRICE GROWTH RATING 1..100 | 37 | 46 | |
P/E GROWTH RATING 1..100 | 54 | 9 | |
SEASONALITY SCORE 1..100 | 13 | 65 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
AZN's Valuation (65) in the Pharmaceuticals Major industry is in the same range as GSK (81). This means that AZN’s stock grew similarly to GSK’s over the last 12 months.
AZN's Profit vs Risk Rating (13) in the Pharmaceuticals Major industry is in the same range as GSK (37). This means that AZN’s stock grew similarly to GSK’s over the last 12 months.
GSK's SMR Rating (34) in the Pharmaceuticals Major industry is in the same range as AZN (44). This means that GSK’s stock grew similarly to AZN’s over the last 12 months.
AZN's Price Growth Rating (37) in the Pharmaceuticals Major industry is in the same range as GSK (46). This means that AZN’s stock grew similarly to GSK’s over the last 12 months.
GSK's P/E Growth Rating (9) in the Pharmaceuticals Major industry is somewhat better than the same rating for AZN (54). This means that GSK’s stock grew somewhat faster than AZN’s over the last 12 months.
| AZN | GSK | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 44% | 7 days ago 65% |
| Stochastic ODDS (%) | 1 day ago 39% | 1 day ago 40% |
| Momentum ODDS (%) | 1 day ago 65% | 1 day ago 62% |
| MACD ODDS (%) | 1 day ago 57% | 1 day ago 63% |
| TrendWeek ODDS (%) | 1 day ago 45% | 1 day ago 55% |
| TrendMonth ODDS (%) | 1 day ago 56% | 1 day ago 58% |
| Advances ODDS (%) | 14 days ago 57% | 28 days ago 63% |
| Declines ODDS (%) | 1 day ago 45% | 1 day ago 55% |
| BollingerBands ODDS (%) | 1 day ago 43% | 1 day ago 42% |
| Aroon ODDS (%) | 1 day ago 54% | 1 day ago 56% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AZN’s FA Score shows that 1 FA rating(s) are green while GSK’s FA Score has 1 green FA rating(s).
- AZN’s FA Score: 1 green, 4 red.
- GSK’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AZN’s TA Score shows that 6 TA indicator(s) are bullish while GSK’s TA Score has 7 bullish TA indicator(s).
- AZN’s TA Score: 6 bullish, 4 bearish.
- GSK’s TA Score: 7 bullish, 3 bearish.
Price Growth
AZN (@Pharmaceuticals: Major) experienced а -1.87% price change this week, while GSK (@Pharmaceuticals: Major) price change was -1.08% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -1.46%. For the same industry, the average monthly price growth was +2.44%, and the average quarterly price growth was +7.11%.
Reported Earning Dates
AZN is expected to report earnings on Feb 11, 2027.
GSK is expected to report earnings on Feb 03, 2027.
Industries' Descriptions
@Pharmaceuticals: Major (-1.46% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
Advertisement
AZN and
Correlation & Price change
A.I.dvisor indicates that over the last year, AZN has been loosely correlated with BIIB. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if AZN jumps, then BIIB could also see price increases.
| Ticker / NAME | Correlation To AZN | 1D Price Change % | ||
|---|---|---|---|---|
| AZN | 100% | -0.69% | ||
| BIIB - AZN | 48% Loosely correlated | +0.06% | ||
| GILD - AZN | 39% Loosely correlated | -0.67% | ||
| GSK - AZN | 28% Poorly correlated | -1.23% | ||
| MRK - AZN | 26% Poorly correlated | -0.59% | ||
| NVS - AZN | 26% Poorly correlated | -1.80% | ||
More | ||||
GSK and
Correlation & Price change
A.I.dvisor indicates that over the last year, GSK has been loosely correlated with NVS. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if GSK jumps, then NVS could also see price increases.